Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
Author Information
Author(s): Chiu Shi-Hsun, Wu Wen-Tien, Yao Ting-Kuo, Peng Cheng-Huan, Yeh Kuang-Ting
Primary Institution: Tzu Chi University
Hypothesis
What are the cardiovascular implications of sclerostin inhibition through romosozumab in osteoporosis treatment?
Conclusion
Romosozumab is effective for osteoporosis treatment but requires careful cardiovascular risk assessment, especially in high-risk populations.
Supporting Evidence
- Romosozumab significantly improves bone mineral density and reduces fracture risk.
- Clinical trials report an increased incidence of major adverse cardiovascular events in patients with pre-existing conditions.
- Long-term studies are needed to evaluate chronic safety.
Takeaway
Romosozumab helps strengthen bones but might also cause heart problems, so doctors need to check heart health before using it.
Methodology
This review synthesizes data from clinical trials and observational studies to evaluate the cardiovascular safety of romosozumab.
Potential Biases
Potential publication bias may favor studies reporting positive outcomes for romosozumab's efficacy.
Limitations
Most studies have short follow-up periods and may not include diverse patient populations, limiting generalizability.
Participant Demographics
The review primarily focuses on postmenopausal women and men with osteoporosis, with limited representation of high-risk groups.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website